Parkinson preclinical research
44 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Richard MITRY
Scoop.it!

Early Screening Tools for Parkinson’s Disease

A smell test could someday be one of the tools to screen for people at risk of developing Parkinson's disease, according to a new Mayo Clinic study. “Parkinson's ...
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

A noninvasive avenue for Parkinson's disease gene therapy - Nanotechnology News (press release)

A noninvasive avenue for Parkinson's disease gene therapy - Nanotechnology News (press release) | Parkinson preclinical research | Scoop.it
A noninvasive avenue for Parkinson's disease gene therapy
Nanotechnology News (press release)
...
more...
No comment yet.
Rescooped by Richard MITRY from Parkinson preclinical research
Scoop.it!

Compounds Protecting Neurons in ALS and Parkinson's Disease

Compounds Protecting Neurons in ALS and Parkinson's Disease | Parkinson preclinical research | Scoop.it
A recently identified class of chemical compounds has been shown to block nerve cell death in animal models of both Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Via TEAM Mike Lopez Memorial Foundation |Find us on Twitter:@TEAMCUREALS, Richard MITRY
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

GDNF not needed by the midbrain dopamine system - Medical Xpress

GDNF not needed by the midbrain dopamine system - Medical Xpress | Parkinson preclinical research | Scoop.it
A key factor in the motor symptoms associated with Parkinson's disease is the gradual destruction of dopamine neurons.
more...
No comment yet.
Rescooped by Richard MITRY from Multiple sclerosis New Drugs Review
Scoop.it!

Glialogix Research

Glialogix Research | Parkinson preclinical research | Scoop.it
Glialogix is an emerging biopharma company founded by two PhD scientists with extensive experience in target discovery, validation and preclinical development.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 2, 2014 4:23 AM

GLX1112 is an improved proprietary formulation of an existing FDA-approved drug that has been in clinical use for more than 50 years for non-neurological indications, where it is dosed chronically. 

The current oral formulation of the existing drug has poor oral bioavailability that would limit its use in CNS indications. Additionally, it is associated with dose-dependent toxicity in the gastrointestinal (GI) tract, including nausea, vomiting and diarrhea. 

GLX1112 is a new optimized formulation of the existing drug that was formulated using proprietary drug-polymer technology. The improved formulation is expected to address the limitations of the existing drug and to enable safer use in the CNS. In a rodent model, GLX1112 improves bioavailability three-fold relative to the current oral formulation of the parent drug. By increasing bioavailability, GLX1112 is expected to reduce local GI toxicity and to allow optimal twice daily oral dosing for diseases of the central nervous system.


Our approach reduces efficacy risk. The parent drug of GLX1112 has already been tested in MS patients. In a previously published Phase 2 clinical trial in MS, a statistically significant effect was seen in progressive MS patients, although subjects likely received a sub-optimal dose that likely limited efficacy. GLX1112, the new proprietary formulation of the drug tested in the Phase 2 clinical trial, is designed to provide appropriate dosing to patients with progressive MS.


Our approach reduces toxicology and pharmacokinetic risks. The safety and pharmacokinetic profile of the GLX1112 API in humans is well understood and acceptable for use in the patient population. GLX1112 is not a new molecular entity (NME) but, rather, an improved, proprietary formulation of an FDA-approved drug.


Pre-clinical validation in multiple neurodegenerative disease models. The parent drug of GLX1112 has demonstrated efficacy in published studies using animal models of MS, ALS, and neuropathic pain. Activity across different neurodegenerative disease models strongly supports the proposed therapeutic mechanism-of-action.


Glialogix and National Multiple Sclerosis Society Enter Into Collaboration to Support Development of a New Oral Therapy for Progressive Multiple Sclerosis 
September 30, 2014

Scooped by Richard MITRY
Scoop.it!

Addex's mGlu2 NAM shows protection in preclinical model of ischemic neuronal ... - pharmabiz.com

Addex's mGlu2 NAM shows protection in preclinical model of ischemic neuronal ... - pharmabiz.com | Parkinson preclinical research | Scoop.it
Addex's mGlu2 NAM shows protection in preclinical model of ischemic neuronal death
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Eltoprazine could tackle dyskinesia side effect in Parkinson's disease, study ... - The Pharmaceutical Journal

Eltoprazine could tackle dyskinesia side effect in Parkinson's disease, study ... - The Pharmaceutical Journal | Parkinson preclinical research | Scoop.it
Researchers have evaluated the use of eltoprazine, a selective partial agonist at the 5-HT1A and 5-HT1B receptors, for its ability to counteract dyskinesias.
more...
No comment yet.
Rescooped by Richard MITRY from Sustain Our Earth
Scoop.it!

Potential new class of drugs protects nerve cells in models of Parkinson's disease, amyotrophic lateral sclerosis

Potential new class of drugs protects nerve cells in models of Parkinson's disease, amyotrophic lateral sclerosis | Parkinson preclinical research | Scoop.it
Researchers at the University of Iowa and the University of Texas Southwestern Medical Center in Dallas, have identified a new class of small molecules that block nerve cell death in animal models of Parkinson's disease and amyotrophic lateral...

Via SustainOurEarth
more...
No comment yet.
Rescooped by Richard MITRY from #ALS AWARENESS #LouGehrigsDisease #PARKINSONS
Scoop.it!

Compounds Protecting Neurons in ALS and Parkinson's Disease

Compounds Protecting Neurons in ALS and Parkinson's Disease | Parkinson preclinical research | Scoop.it
A recently identified class of chemical compounds has been shown to block nerve cell death in animal models of both Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Via TEAM Mike Lopez Memorial Foundation |Find us on Twitter:@TEAMCUREALS
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Frontiers | Parkinson’s disease: animal models and dopaminergic cell vulnerability | Frontiers in Neuroanatomy

Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the global population over 65 years of age. A hallmark feature of PD is the degeneration of the dopamine (DA) neu...
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Animal models for Parkinson Disease? | Blog's Syncrosome

Animal models for Parkinson Disease? | Blog's Syncrosome | Parkinson preclinical research | Scoop.it
We just came back from the last edition of “World Congress on Parkinson's Disease and Related Disorders” that took place last week on Geneva, Switzerland. This International congress brought together leading clinical and pre-clinical ...
more...
No comment yet.
Rescooped by Richard MITRY from Neuroscience: Parkinson's disease
Scoop.it!

Parkinson disease: Low vitamin D and Parkinson disease a causal conundrum

Parkinson disease: Low vitamin D and Parkinson disease a causal conundrum | Parkinson preclinical research | Scoop.it

Via Juan Piña-Crespo
more...
No comment yet.
Rescooped by Richard MITRY from Neuroscience: Parkinson's disease
Scoop.it!

Identification and rescue of α-Synuclein toxicity in Parkinson's disease-associated neurons

Identification and rescue of α-Synuclein toxicity in Parkinson's disease-associated neurons | Parkinson preclinical research | Scoop.it

Via Jacob Blumenthal, Juan Piña-Crespo
more...
Jacob Blumenthal's curator insight, November 1, 2013 6:22 AM

Parkinson's disease (PD) is a neurodegenerative disease typically characterized by loss of dopaminergic neurons in the substantia nigra region of the brain. Parkinson's disease dementia (PDD) affects 80% of PD patients, and is pathologically related to neuronal loss and aggregation of α-Synuclein (αSyn) (encoded by the SNCA gene) in the cerebral cortex area of the brain. In order to study the molecular characteristics of and mechanisms underlying PDD, researchers from the Whitehead Institute have generated induced pluripotent stem (iPS) cells from patient skin cells, harboring α-Synuclein mutations (A53T). In a parallel experiment, (click the image to read more).

 

Explore dopaminegic neurons development:

http://discovery.lifemapsc.com/in-vivo-development/dopaminergic-neurons

Scooped by Richard MITRY
Scoop.it!

Anti-Inflammatory Drug Reduces Parkinson's Neuron Loss, Motor Deficits In ... - Medical Daily

Researchers may be one step closer to stopping early progression of Parkinson’s disease by targeting the inflammation that kills neurons.
more...
No comment yet.
Rescooped by Richard MITRY from Parkinson preclinical research
Scoop.it!

Effect of nicotine on L-dopa-induced dyskinesia in animal models of... - PubMed - NCBI

Neurol Sci. 2014 May;35(5):653-62. doi: 10.1007/s10072-014-1652-5. Epub 2014 Feb 9. Meta-Analysis; Research Support, Non-U.S. Gov't; Review

Via GolfKahn, Richard MITRY
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96 ... - Stockhouse

Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96 ... - Stockhouse | Parkinson preclinical research | Scoop.it
Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96 ...
Stockhouse
Prior to initiating clinical trials, Prothena demonstrated the efficacy of PRX002 in various cellular and animal models of synuclein-related disease.
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Research and Markets: Global Parkinson's Disease Pipeline Highlights 2014-2015 - Business Wire (press release)

Research and Markets: Global Parkinson's Disease Pipeline Highlights 2014-2015 - Business Wire (press release) | Parkinson preclinical research | Scoop.it
Research and Markets (http://www.researchandmarkets.com/research/dck497/parkinsons) has announced the addition of the "Parkinson's Disease Pipeli
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round - FierceBiotech

Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round - FierceBiotech | Parkinson preclinical research | Scoop.it
Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson's disease,...
more...
No comment yet.
Rescooped by Richard MITRY from VapeHalla!
Scoop.it!

Effect of nicotine on L-dopa-induced dyskinesia in animal models of... - PubMed - NCBI

Neurol Sci. 2014 May;35(5):653-62. doi: 10.1007/s10072-014-1652-5. Epub 2014 Feb 9. Meta-Analysis; Research Support, Non-U.S. Gov't; Review

Via GolfKahn
more...
No comment yet.
Scooped by Richard MITRY
Scoop.it!

What have we learned from animal models?

Dr. Miquel Vila explains what his research with animal models has taught him regarding cell death and finding a cure for Parkinson's disease. Listen to the f...
more...
No comment yet.
Rescooped by Richard MITRY from Sustain Our Earth
Scoop.it!

Potential new class of drugs protects nerve cells in models of Parkinson's disease, amyotrophic lateral sclerosis

Potential new class of drugs protects nerve cells in models of Parkinson's disease, amyotrophic lateral sclerosis | Parkinson preclinical research | Scoop.it
Researchers at the University of Iowa and the University of Texas Southwestern Medical Center in Dallas, have identified a new class of small molecules that block nerve cell death in animal models of Parkinson's disease and amyotrophic lateral...

Via SustainOurEarth
more...
No comment yet.
Rescooped by Richard MITRY from Home tips
Scoop.it!

Caffeine and Parkinson's Disease - Heath tips

Caffeine and Parkinson's Disease - Heath tips | Parkinson preclinical research | Scoop.it
The demonstration that caffeine and more specific A2A antagonists protect dopaminergic nigrostriatal neurons in multiple animal models of PD has pathophysiological, epidemiological, and therapeutic significance for Parkinson's Disease.

Via Jean-Paul Marat
more...
Jean-Paul Marat's curator insight, January 26, 2014 11:07 AM

The demonstration that caffeine and more specific A2A antagonists protect dopaminergic nigrostriatal neurons in multiple animal models of PD has pathophysiological, epidemiological, and therapeutic significance for PD.

Read more: http://health.tipsdiscover.com/caffeine-parkinsons-disease/#ixzz2rWNZWJNM

Scooped by Richard MITRY
Scoop.it!

Could A Treatment For Parkinson's Reverse The Effects Of Early Life ...

Could A Treatment For Parkinson's Reverse The Effects Of Early Life ... | Parkinson preclinical research | Scoop.it
But the work had one other interesting result: when the social behaviour of the animals was being tested two rats exposed to prenatal stress put together didn't play, but, surprisingly, the interaction of one of these and a normal ...
more...
No comment yet.
Rescooped by Richard MITRY from Neuroscience: Parkinson's disease
Scoop.it!

Pimavanserin may benefit patients with Parkinson's disease psychosis : The Lancet

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. By - Jeffrey Cummings MD, Stuart Isaacson MD, Roger Mills MD, Hilde Williams, Kathy Chi...

Via Juan Piña-Crespo
more...
No comment yet.
Rescooped by Richard MITRY from Neuroscience: Parkinson's disease
Scoop.it!

Alpha synuclein in LRRK2 brains | Degenerating neurons

Alpha synuclein in LRRK2 brains | Degenerating neurons | Parkinson preclinical research | Scoop.it
First author Adamantios Mamais tells us about his recent publication in Neurobiology of Disease: At the Queen Square Brain Bank (part of the UCL Institute of Neurology) we hold a large collection of post-mortem human brain ...

Via Juan Piña-Crespo
more...
No comment yet.